Yes, many cancer treatments are designed to target specific mutations:
1. Targeted Therapies: Drugs like imatinib for BCR-ABL fusion in chronic myeloid leukemia target specific genetic abnormalities. 2. Immunotherapies: These treatments, including checkpoint inhibitors, can be effective against cancers with high mutational burdens. 3. PARP Inhibitors: These drugs are particularly effective in cancers with BRCA1/2 mutations.
